No connection

Search Results

PLUR

BEARISH
$3.51 Live
Pluri Inc. · NASDAQ
Target $12.0 (+241.9%)
$2.82 52W Range $7.13

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 17, 2026
Market cap
$35.28M
P/E
N/A
ROE
N/A
Profit margin
N/A
Debt/Equity
N/A
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
95%
PLUR exhibits critical financial distress, highlighted by a Piotroski F-Score of 1/9 and a negative Price-to-Book ratio of -2.40, indicating negative shareholder equity. The company is facing a severe liquidity crisis with a current ratio of 0.43, suggesting it cannot meet its short-term obligations. While recent quarterly earnings have beaten estimates, the operating margin of -3285.86% and a bearish technical trend (0/100) underscore a high risk of insolvency or significant shareholder dilution. The valuation is disconnected from fundamentals, trading at a high Price/Sales multiple of 26.35 despite sluggish revenue growth.

Key Strengths

Recent quarterly earnings beats (3 of last 4 quarters)
Positive YoY EPS growth (+71%)
Gross margin remains positive at 40.63%
Slight positive revenue growth (7% YoY)
High optimistic analyst target price of $12.00

Key Risks

Negative equity (P/B -2.40) indicating insolvency risk
Severe liquidity shortage (Current Ratio 0.43)
Catastrophic operating losses (-3285.86% margin)
Extreme valuation premium (P/S 26.35) for a low-growth biotech
Long-term value destruction (-89.3% 5-year price change)

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
10
Weak
Value
5
Future
30
Past
10
Health
5
Dividend
0
AI Verdict
High Risk / Speculative
Key drivers: Negative Equity, Liquidity Crisis, Piotroski F-Score 1/9, Extreme Operating Losses
Confidence
90%
Value
5/100

Stock is fundamentally overvalued relative to its negative book value and low revenue.

Positives
No standout positives identified.
Watchpoints
  • P/B is -2.40
  • P/S is 26.35
  • No Graham Number available due to negative earnings
Future
30/100

Growth is insufficient to offset the current rate of capital depletion.

Positives
  • Improving EPS trend
  • Positive revenue growth
Watchpoints
  • Low revenue growth (7%) compared to sector average
  • High burn rate
Past
10/100

Long-term performance shows a consistent downward trajectory.

Positives
No standout positives identified.
Watchpoints
  • 5Y Change: -89.3%
  • Consistent history of negative earnings
Health
5/100

Financial health is in a critical state; high probability of needing emergency capital.

Positives
No standout positives identified.
Watchpoints
  • Piotroski F-Score 1/9
  • Current Ratio 0.43
  • Negative Equity
Dividend
0/100

Dividend strength is 0/100.

Positives
No standout positives identified.
Watchpoints
  • No dividend paid
  • No capacity for dividends

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$3.51
Analyst Target
$12.0
Upside/Downside
+241.9%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for PLUR and closest competitors.

Updated 2026-04-16
PLU
Pluri Inc.
Primary
5Y
-89.3%
3Y
-51.8%
1Y
-3.0%
6M
-19.3%
1M
+8.7%
1W
+3.5%
LGV
Longeveron Inc.
Peer
5Y
-98.3%
3Y
-96.0%
1Y
-14.1%
6M
+42.7%
1M
+42.7%
1W
+8.4%
NMT
NeuroOne Medical Technologies Corporation
Peer
5Y
-88.5%
3Y
-57.8%
1Y
+32.2%
6M
-19.5%
1M
+1.4%
1W
-12.1%
ATR
Atara Biotherapeutics, Inc.
Peer
5Y
-98.9%
3Y
-95.6%
1Y
-24.7%
6M
-54.9%
1M
-70.3%
1W
+15.0%
BDM
Baird Medical Investment Holdings Limited
Peer
5Y
-89.3%
3Y
-90.0%
1Y
-87.4%
6M
-49.5%
1M
-26.9%
1W
-10.4%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
N/A
Forward P/E
-1.85
PEG Ratio
N/A
P/B Ratio
-2.4
P/S Ratio
26.35
EV/Revenue
47.15
EV/EBITDA
-2.58
Market Cap
$35.28M

Profitability

Profit margins and return metrics

Profit Margin N/A
Operating Margin -3285.86%
Gross Margin 40.63%
ROE N/A
ROA -50.6%

Growth

Revenue and earnings growth rates

Revenue Growth +7.0%
Earnings Growth N/A
Q/Q Revenue Growth +7.03%
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
N/A
Current Ratio
0.43
Weak
Quick Ratio
0.39
Poor
Cash/Share
$1.24

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$0.0B
Gross Margin
43.4%
Op. Margin
-3285.9%
Net Margin
-3304.5%
Total Assets
$0.0B
Liabilities
$0.0B
Equity
$-0.0B
Debt/Equity
-2.73x
Operating CF
$-0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
109%

Quarterly Earnings History

EPS performance vs analyst estimates

2025-11-12
$-0.65
+12.2% surprise
2025-09-17
$-1.0
-37.0% surprise
2023-02-13
$-1.92
+25.0% surprise
2022-11-10
$-1.52
+40.6% surprise

Healthcare Sector Comparison

Comparing PLUR against 393 companies in the Healthcare sector (24 bullish, 129 neutral, 240 bearish)
Revenue Growth
7.0%
This Stock
vs
124.21%
Sector Avg
-94.4% (Slower)
Current Ratio
0.43
This Stock
vs
4.56
Sector Avg
-90.6% (Weaker)

Similar Companies

Peer comparison within the same industry

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

MANIEU ALEXANDRE WEINSTEIN
Director and Beneficial Owner of more than 10% of a Class of Security
Stock Award
2025-12-08
625,000 shares · $1,956,250
ABERMAN ZALMAN
Director
Stock Award
2025-12-04
346 shares
YANAY YAKY
Chief Executive Officer
Stock Award
2025-12-04
6,588 shares
SHEMESH-RASMUSSEN MAITAL
Director
Stock Award
2025-12-04
699 shares
LEVI RAMI AVRAHAM
Director
Stock Award
2025-12-04
653 shares
MANIEU ALEXANDRE WEINSTEIN
Director and Beneficial Owner of more than 10% of a Class of Security
Stock Award
2025-12-04
519 shares
ZALTS LIAT
Chief Financial Officer
Stock Award
2025-12-04
3,660 shares
AJCHENBAUM EITAN
Director
Stock Award
2025-12-04
668 shares
AJCHENBAUM EITAN
Director
Stock Award
2025-11-12
11,685 shares
MANIEU ALEXANDRE WEINSTEIN
Director and Beneficial Owner of more than 10% of a Class of Security
Option Exercise
2025-10-29
1,002,169 shares · $100
Insider transactions can signal confidence or concerns about company prospects

SEC Filings

Recent regulatory filings from the SEC EDGAR database

8-K
CURRENT REPORT
2026-03-27
8-K
CURRENT REPORT
2026-03-02

Pluribus filed a current report on March 2, 2026, likely announcing its annual financial results for the preceding fiscal year.

10-Q
QUARTERLY REPORT
2026-02-12

PLUR filed its quarterly report (Form 10-Q) on February 12, 2026. The provided excerpts do not contain specific financial highlights or detailed risk factors.

8-K
CURRENT REPORT
2026-01-22

Pluribus filed a current report on January 22, 2026, likely to announce its fourth quarter and full-year financial results.

8-K
CURRENT REPORT
2025-12-09
10-Q
QUARTERLY REPORT
2025-11-12

PLUR filed its quarterly report (Form 10-Q) on November 12, 2025. Specific financial highlights and risk factors were not provided in the available filing metadata.

8-K
CURRENT REPORT
2025-10-16

PLUR filed a current report on October 16, 2025, likely disclosing material corporate developments or quarterly financial results.

10-K
ANNUAL REPORT
2025-09-17

PLUR filed its annual 10-K report on September 17, 2025, which includes sections on business operations, financial condition, and risk factors. No specific financial highlights or risk details were provided in the available excerpts.

8-K
CURRENT REPORT
2025-09-12
8-K
CURRENT REPORT
2025-09-11
8-K
CURRENT REPORT
2025-07-03
DEF 14A
DEFINITIVE PROXY STATEMENT
2025-05-27
8-K
CURRENT REPORT
2025-05-27
10-Q
QUARTERLY REPORT
2025-05-13
8-K
CURRENT REPORT
2025-05-08
Data sourced from SEC EDGAR. AI summaries generated automatically.

Past News Coverage

Recent headlines mentioning PLUR from our newsroom.

Newest → oldest
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Home
Terminal
AI
Markets
Profile